The two most common non-oncogene-driven mutations in lung adenocarcinoma, STK11 (serine/threonine kinase 11) and KEAP1 (Kelch-like ECH-associated protein 1) mutations, were found to be predictors of poor outcomes in patients with NSCLC treated with immunotherapy [17]. This evidence concerns the gene KEAP1 and lung adenocarcinoma.